Search tips
Search criteria 


Logo of jbcThe Journal of Biological Chemistry
J Biol Chem. 2015 February 20; 290(8): 5203–5213.
Published online 2015 January 7. doi:  10.1074/jbc.M114.618124
PMCID: PMC4335253

Prevalence and Gene Characteristics of Antibodies with Cofactor-induced HIV-1 Specificity*An external file that holds a picture, illustration, etc.
Object name is sbox.jpg


The healthy immune repertoire contains a fraction of antibodies that bind to various biologically relevant cofactors, including heme. Interaction of heme with some antibodies results in induction of new antigen binding specificities and acquisition of binding polyreactivity. In vivo, extracellular heme is released as a result of hemolysis or tissue damage; hence the post-translational acquisition of novel antigen specificities might play an important role in the diversification of the immunoglobulin repertoire and host defense. Here, we demonstrate that seronegative immune repertoires contain antibodies that gain reactivity to HIV-1 gp120 upon exposure to heme. Furthermore, a panel of human recombinant antibodies was cloned from different B cell subpopulations, and the prevalence of antibodies with cofactor-induced specificity for gp120 was determined. Our data reveal that upon exposure to heme, ~24% of antibodies acquired binding specificity for divergent strains of HIV-1 gp120. Sequence analyses reveal that heme-sensitive antibodies do not differ in their repertoire of variable region genes and in most of the molecular features of their antigen-binding sites from antibodies that do not change their antigen binding specificity. However, antibodies with cofactor-induced gp120 specificity possess significantly lower numbers of somatic mutations in their variable region genes. This study contributes to the understanding of the significance of cofactor-binding antibodies in immunoglobulin repertoires and of the influence that the tissue microenvironment might have in shaping adaptive immune responses.

Keywords: Antibody, Cloning, Heme, Human Immunodeficiency Virus (HIV), Immunoglobulin G (IgG), gp120, Cofactors


Immune repertoires of all healthy individuals contain antibodies (Abs)2 that are able to interact with different low molecular weight compounds, including biologically relevant cofactors as riboflavin, FMN, FAD, heme (Fe(II) protoporphyrin IX), and ATP, as well as metal ions (1,7). The binding affinity of riboflavin, FAD, and FMN to Abs is higher than the binding affinity to known plasma transporters of heterocyclic compounds such as albumin (1, 2). A fraction of Abs in normal serum also bind with high affinity to several xenobiotic organic compounds such as dinitrophenyl and naphthalene derivatives, as well as azo compounds (8,12). The presence of cofactor-binding Abs in normal human immune repertoires has been recently used for specific targeting of cancer cells or viruses as well as for catalysis of redox reactions, thus demonstrating the possibility to develop innovative therapeutic strategies based on cofactor-binding Abs (13,17). However, the origin, molecular characteristics, and physiopathological significance of natural cofactor-binding Abs in human immune repertoires remain not well understood.

Cofactor-binding Abs have initially been proposed to serve solely as inert carriers of biologically relevant heterocyclic molecules in plasma (1, 2). More recent studies, however, revealed that the binding of certain cofactors, i.e. heme, has a considerable impact on the antigen binding specificity of Abs. Thus, it has been demonstrated that normal immune repertoires contain a fraction of Abs that can acquire novel antigen binding specificities upon exposure to heme (7, 18,21). These Abs belong to different immunoglobulin isotypes (IgG, IgA, and IgM), and their exposure to heme results in the appearance of novel binding specificities for both self-derived and pathogen-derived antigens (7, 19, 22). Moreover, it has been observed that heme endows some monoclonal Abs with the capability to recognize numerous unrelated antigens, i.e. they acquire antigen binding polyreactivity (7, 23). Previous studies have demonstrated that the post-translational acquisition of novel antigen binding specificities by cofactor binding correlates with an increased anti-inflammatory activity of IgG (24). Importantly, extracellular heme can be released in large quantities as a result of intravascular hemolysis or tissue damage in numerous disease conditions (25,27). This may result in interactions of heme with circulating cofactor-binding Abs and induction of novel antigen binding specificities in vivo.

Little is known, however, about the frequencies of Abs with cofactor-inducible antigen specificities in human immune repertoires and the molecular features of the variable regions that determine their sensitivity to heme. To address these questions, we used a repertoire of human recombinant Abs obtained upon cloning of variable regions, amplified by single-cell PCR technology from different B cell subpopulations, and fused to Fcγ1 constant chain. We demonstrated that after heme exposure, ~24% of Abs in the repertoire gain an ability to recognize different variants of a highly heterogeneous envelope glycoprotein, gp120 of HIV-1. Most of the gp120 reactive Abs were also polyreactive and bound to unrelated proteins. Further, we analyzed the gene characteristics of variable regions of monoclonal Abs that may explain their tendency to acquire novel antigen binding specificities upon contact with heme.


Proteins and Antibodies

Recombinant envelope glycoprotein 120 (gp120) from HIV-1 strains BaL (clade B), CN54 (clade C), 96ZM651 (clade C), and 93TH975 (clade A/E) was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, at the National Institutes of Health. Recombinant gp120 from strains 92RW020 (clade A) and JRCSF (clade B) were purchased from Immune Technology Corp. (New York, NY).

Human transferrin, human hemoglobin, and porcine tubulin were obtained from Sigma-Aldrich. Human factor IX was obtained from LFB, (Les Ulis, France), and pneumococcal C-polysaccharide (pnC) was obtained from Statens Serum Institut, (Copenhagen, Denmark). Human immunodeficiency virus immune globulin (HIVIg) was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, at the National Institutes of Health. Two commercial IVIg preparations, Intratect (Biotest AG, Dreieich, Germany) and Endobulin S/D (Baxter, Deerfield, IL), were used as a source of normal pooled human immunoglobulins G. The repertoire of human antibodies was described previously in Refs. 28 and 29. Briefly, the variable genes encoding the antibody heavy and light chains were amplified by single-cell PCR from synovial tissue of rheumatoid arthritis patients, cloned in PUC19 vector containing the genes encoding the constant Fc-γ1 or λ/κ regions, respectively, and expressed using HEK293 cells (28).


All reagents used in the study were analytical grade quality. Stock solutions of hematin (ferriprotoporphyrin IX hydroxide) were prepared by dissolving hemin (Fluka, St. Louis, MO) to concentrations of 1 mm in 0.05 n solution of NaOH or 20 mm in 0.1 n solution of NaOH. The treatment of immunoglobulins was always performed with freshly prepared hematin, at dim light conditions.


Reactivity of IgG Repertoire to gp120

Ninety-six-well polystyrene plates (Nunc MaxiSorp, Roskilde, Denmark) were coated with recombinant HIV-1 gp120 variants, 92RW020, BaL, JRCSF, or CN54, diluted to 5 μg/ml in PBS. After incubation for 3 h at 22 °C, the residual binding sites on plates were blocked by PBS containing 0.25% Tween 20 (Sigma-Aldrich). In the first experimental setting, IVIg (67 μm, 10 mg/ml) diluted in PBS were exposed to a fixed concentration of heme (50 μm). After a 30-min incubation on ice, native and heme-exposed immunoglobulins were diluted serially in PBS containing 0.05% Tween 20 (PBS-T) to final concentrations of 1000, 333, 111, 37, 12, 4, 1.3, 0.45, 0.15, and 0.05 μg/ml for IVIg and HIVIg and then incubated with gp120 BaL-coated plates for 2 h at 22 °C. In the second experimental setting, a fixed concentration of IVIg (20 μm, 3 mg/ml) was exposed for 30 min on ice to increasing concentrations of heme: 0, 0.5, 1, 2, 4, 8, 16, 32, and 64 μm, respectively. Heme-exposed immunoglobulins were diluted in PBS-T to 150 μg/ml and incubated for 2 h at 22 °C with plates coated with gp120 variants: 92RW020, BaL, JRCSF, or CN54. After incubation with antibodies, in both experimental variants, microtitration plates were washed extensively with PBS-T and incubated with a peroxidase-conjugated mouse anti-human IgG (clone JDC-10, Southern Biotech, Birmingham, AL) for 1 h at 22 °C. Immunoreactivity of IgG were revealed by measuring the absorbance at 492 nm after the addition of peroxidase substrate, o-phenylenediamine dihydrochloride (Sigma-Aldrich) and stopping the reaction by the addition of 2 n HCl.

Reactivity of IgG Repertoire to Autoantigens and pnC

Ninety-six-well polystyrene plates (Nunc MaxiSorp) were coated with human transferrin, human factor IX, human hemoglobin (apo-form), and pnC diluted to 10 μg/ml in PBS as well as with porcine tubulin diluted to 5 μg/ml in PBS. After incubation for 3 h at 22 °C, the residual binding sites on plates were blocked by PBS containing 0.25% Tween 20. For the treatment with heme, all recombinant Abs were diluted to 50 μg/ml and exposed to 10 μm final concentration of hematin. As a positive control, IVIg at 10 μm (1.5 mg/ml) was treated with 10 μm of hematin. After 30 min of incubation on ice, native and heme-exposed monoclonal Abs were first diluted with TBS-T (0.1% Tween 20) to final IgG concentrations of 25 μg/ml and incubated for 2 h at 4 °C. Further, the Abs were diluted in PBS-T to 6.25 μg/ml and incubated for 2 h at 22 °C with plates coated with the studied proteins or pnC. Heme-exposed IVIg diluted to 50 μg/ml in PBS-T was incubated on each plate. The next steps of ELISA were identical as these described above.

The binding of native and heme-exposed Abs to particular antigen was expressed as a percentage of the binding of the heme-exposed IVIg. The monoclonal Abs that demonstrated binding intensity toward the given antigen above a threshold value (defined as the mean reactivity of all native Abs plus five standard deviations) upon heme exposure were considered as heme-sensitive.

Size-exclusion Chromatography

Molecular composition of native and heme-exposed pooled IgG was studied by using an FPLC ÄKTA purifier (GE Healthcare), equipped with a Superose 12 10/300 column. Pooled IgG was diluted to 20 μm in PBS and exposed to 4, 32, and 64 μm of heme. The chromatograms were recorded by using a wavelength of 280 nm.

Screening of Recombinant IgG1 for Gain of Reactivity to gp120 and Repertoire Analyses

Viral antigens from 20 μg/ml solutions in PBS (pH 7.4) were immobilized on nitrocellulose membranes using a Miniblot apparatus (Immunetics, Boston, MA). Two channels were loaded for each antigen and incubated at 4 °C overnight. Membranes were removed from the Miniblot apparatus, blocked with TBS-Tween 0.1%, and mounted perpendicularly in the Miniblot apparatus. Antibodies were treated at a 40 μg/ml concentration in PBS, either with hematin solubilized in 0.05 n NaOH (final heme concentration 20 μm) or with vehicle only (0.05 n NaOH). After a 30-min incubation, hematin-treated and native antibodies were diluted 2-fold in TBS containing 0.1% Tween 20 (TBS-T) and loaded on Miniblot channels. Likewise, a 1.5 mg/ml (~10 μm) IVIg solution in PBS was treated either with hematin (final concentration, 20 μm) or with vehicle only (0.05 n NaOH), diluted 200 times in TBS-T, and then loaded on the Miniblot system. After a 1-h incubation at room temperature, nitrocellulose membranes were removed from the Miniblot apparatus, washed for 1 h with TBS-Tween 0.1%, and incubated with horseradish peroxidase-conjugated anti-human IgG antibody (Southern Biotech). Enzymatic reaction was performed using the Pierce ECL Western blotting substrate (Thermo Scientific), and chemiluminescence was developed by 0.5-, 1-, and 4-min exposure of multipurpose film (GE Healthcare, Little Chalfont, UK).

Spot intensities at the intersections of antigens and antibodies-loaded channels were evaluated by densitometry using the Chemi-Capt/Bio-1D software (Vilber Lourmat, Torcy, France) after subtracting background intensities. Values were normalized to non-saturating IVIg intensity to take into account variations in film exposure times. Exposure time to be included in the analysis was chosen as the one giving the highest signal without saturation, for each antibody. Results are expressed as relative units. Values of the binding intensity to gp120 of each antibody before and after heme exposure were plotted. In each of these plots, a threshold that distinguishes heme-sensitive from non-sensitive antibodies was defined. The threshold was defined as the average index of binding plus three standard deviations obtained for binding of all native antibodies. Antibodies that acquire binding activity to gp120 above these thresholds after heme exposure were defined as sensitive.


The Presence of Heme-induced HIV-1-specific IgG Antibodies in Human Immune Repertoires

First, we tested whether seronegative human repertoires contain Abs that could gain binding to HIV-1 gp120 upon exposure to heme. As a source of IgG from humans, we used pooled human IgG obtained from >1000 different healthy blood donors. Abs from the native IgG preparation bound only negligibly to immobilized gp120 from HIV-1 BaL (clade B) (Fig. 1A). However, exposure of immunoglobulins to heme resulted in acquisition of a strong binding potential for gp120 (Fig. 1A). The binding to gp120 of heme-exposed pooled IgG was, however, less pronounced than the binding of HIVIg, a pooled IgG preparation obtained from HIV-1 seropositive patients. The acquisition of gp120 binding specificity of IgG was further confirmed by immunoblot and SPR analyses (Fig. 1, B and C). In addition to binding to gp120 belonging to gp120 BaL, the exposure of pooled human IgG to heme uncovered binding specificities to divergent variants of gp120 as well: JRCSF (clade B), 92RW020 (clade A), and CN54 (clade C) (Fig. 1D).

Heme induces binding of pooled human IgG to gp120. A, comparison of binding of native IVIg (open circles), heme-exposed IVIg (67 μm IgG/50 μm hematin) (closed squares), and HIVIg (open triangles) to gp120 by ELISA. Ig preparations were ...

To rule out the possibility that the appearance of binding specificity to gp120 is caused by heme-induced aggregation or other changes in molecular integrity of IgG, we studied the molecular composition of pooled immunoglobulins after exposure to heme. Exposure of IgG to heme concentrations that were well above those required for induction of binding to gp120 did not result in significant change in the molecular composition of the immunoglobulin preparation, as evident by size-exclusion chromatography (Fig. 2). These results rule out heme-induced aggregation of IgG and nonspecific increase in IgG valency as putative contributors to the induced binding to gp120.

Molecular profiles of human IgG after heme exposure. Elution profiles obtained by size-exclusion chromatography (Superose 12 10/300 column) after injection of pooled IgG (20 μm), native or exposed to increasing concentrations of heme (4, 32, and ...

In summary, our results demonstrate that normal human immunoglobulin repertoires contain Abs that gain binding potential to divergent strains of HIV-1 gp120 after exposure to the redox-active cofactor heme.

The Prevalence of Heme-induced HIV-1-specific Immunoglobulins in Human Immune Repertoires

To determine the prevalence of Abs that gain binding specificity to HIV-1 gp120 after heme exposure, and to decipher the molecular correlates responsible for the acquisition of HIV-1 gp120 binding, we used a repertoire of 97 human recombinant monoclonal immunoglobulins, cloned from naive and memory B cells, as well as plasma cells from seronegative individuals. All variable regions were expressed on an IgG1 framework, and therefore, all Abs have identical constant regions. This allowed us to examine the contribution of the nature of the variable regions for acquisition of gp120 binding specificity.

A Miniblot system was used to assess the reactivity of monoclonal Abs toward three divergent variants of HIV-1 gp120: 92RW020, BaL, and JRCSF. The binding of each monoclonal Ab was compared before and after exposure to heme. A representative result is depicted on Fig. 3A. It shows that out of nine antibodies tested, only Ab69, Ab72, and Ab76 gain binding potential for gp120 after exposure to heme. Immunoblot data were quantified using densitometry analyses (Fig. 3B). Altogether, 23 of the 97 monoclonal Abs (23.7%) gained significant binding activity to gp120 after heme exposure (Fig. 3C). Details about gene characteristics, sequence of complementarity determining regions 3 (CDR3) regions, and mutational status of variable domains of heavy and light Ig chains of the heme-sensitive antibodies are presented in supplemental Table 1. Among Abs that bind significantly to gp120, certain ones gained much higher binding potential than others (Fig. 3B and Table 1). The variable regions of the monoclonal Abs were cloned from naive (11.4%), memory (30.7%), or plasma B cells (57.9%). Our data reveal that there was no significant difference in the distribution of frequencies of B cell subpopulations from which heme-sensitive and non-sensitive Abs were cloned (Fig. 4A): naive B cells, 10.1% versus 15.7%; memory B cells, 31.9% versus 26.3%; and plasma cells, 58.0% versus 58.0%, respectively. The original isotype of the B cell receptor also did not correlate with the sensitivity to induction of gp120 reactivity of the recombinant Abs (Fig. 4B).

Identification of Abs in human immunoglobulin repertoire that acquire binding activity to gp120 after exposure to heme. A, representative result from immunoblot analysis of interaction of native and heme-exposed human monoclonal Abs with immobilized gp120 ...
Antigen binding characteristics of heme-induced gp120 reactive Abs
Origin of heme-sensitive immunoglobulins. A, distribution of percentages of B cell subpopulations from which Abs that were non-sensitive (ns, left pie chart) or sensitive to heme (right pie chart) were cloned. Differences in the percentages in the B cell ...

Most of the heme-sensitive Abs (18/23) acquired binding potential to at least two distinct gp120 variants included in the study (Fig. 3, A and B, summarized in Table 1). Previous studies have demonstrated that exposure to heme of some monoclonal Abs results in binding to unrelated antigens i.e. Abs acquire polyreactivity (20, 23). To determine whether Abs that gain specificity to gp120 recognize unrelated proteins, we screened the repertoire of monoclonal Abs for reactivity to different protein antigens, transferrin, tubulin, factor IX, and hemoglobin, as well as to pnC. The obtained results demonstrated that most of the monoclonal Abs in the repertoire did not significantly change their antigen binding specificity after contact with heme. However, a fraction of Abs gained a significant reactivity to different protein antigens (Fig. 5A). Interestingly, the exposure to heme did not uncover any Ab reactivity to carbohydrate antigen. Next, we studied whether the Ab reactivity to gp120 induced by heme correlates with acquisition of binding to unrelated proteins. The analyses of data from Fig. 5A revealed that 16 out of 23 heme-sensitive gp120 binding Abs, also acquired reactivity to at least single unrelated protein (summarized in Table 1). Some of heme-induced Abs, however, demonstrated exquisite specificity for gp120. For instance, although heme-exposed Ab47 has the highest binding intensity to the three gp120 variants, this Ab did not bind to any other protein or pnC (Table 1 and Fig. 5B). When Ab47 was excluded from correlation analyses, there was a significant correlation between the intensity of binding of heme-sensitive Abs to gp120 with intensity of binding to unrelated proteins (Fig. 5B). Taken together, these data suggest that most of the heme-induced gp120 binding Abs are polyreactive and that with some exceptions, the binding intensity for recognition of gp120 correlates with binding intensity for binding of unrelated proteins.

Heme-mediated polyreactivity of monoclonal Abs. A, quantitative analyses of reactivity of the repertoire of human monoclonal IgG1 Abs to human transferrin, porcine tubulin, human factor IX, human hemoglobin (apo form), and pneumococcal C-polysaccharide. ...

Finally, we investigated whether the intrinsic polyreactivity of native Abs is a predisposing factor for gain of binding to gp120 after interaction with heme. By using immunoblot analyses, we demonstrated that 8 out of 23 heme-sensitive Abs display polyreactivity in their native state (data not shown) (Table 1). This result implies that natural polyreactivity of Abs is not a determining factor for the potential of Abs to acquire recognition of gp120 and other antigens after interaction with heme.

Molecular Correlates of Heme-induced gp120 Reactivity

The Abs used in the present work were cloned from naive, memory, and plasma B cells isolated from the synovium of three patients with rheumatoid arthritis (29). To understand the molecular correlates of cofactor-induced Ab specificity to gp120, we compared the features of the variable regions of the monoclonal Abs that acquire specificity to gp120 (heme-sensitive) with those that did not (non-sensitive) (Fig. 6). A comparison of the V-gene repertoire of the 97 human monoclonal Abs indicated an unbiased usage of Ig variable region genes, which is typical of a normal human immune repertoire (Fig. 6). The frequency of usage of VH gene families did not differ between the two categories of Abs (Fig. 6A). The observed distribution, with a predominance of VH3 family, followed a trend similar to the distribution of VH gene families found in the IMGT human Ig genes database. Similarly, no difference in the frequency of usage of JH families was observed (Fig. 6A).

Analyses of molecular features of variable regions of heavy and light Ig chains of heme-induced gp120 reactive monoclonal Abs. A, frequency distribution analyses of: gene families encoding heavy chain variable regions (panel 1); gene families encoding ...

The frequencies of somatic mutations in VH regions of non-sensitive Abs showed a Gaussian distribution, typical for immune repertoires (Fig. 6A). In contrast, heme-sensitive Abs had a non-symmetrical distribution of the frequencies of somatic mutations in their VH regions (Fig. 6A). Thus, highly mutated VH regions (with >24 somatic mutations) were significantly less prevalent (p = 0.048, Fisher's exact test) among heme-sensitive as compared with non-sensitive Abs.

The complementarity-determining region of the heavy immunoglobulin chain 3 bears the highest sequence diversity among different CDR loops and plays a central role for recognition of antigen by Abs (30). The distribution of the lengths of CDR H3 regions of heme-sensitive and non-sensitive Abs did not demonstrate significant difference (p = 0.143, Fisher's exact test) (Fig. 6A). Further, the physicochemical characteristics of the CDR H3 regions from both groups of Abs were compared. The distribution of the number of positive, negative, or polar amino acids did not differ significantly between the two types of Abs (Fig. 6A). However, there was a strong tendency for a higher number of negative (p = 0.086, Fisher's exact test) and polar (p = 0.092, Fisher's exact test) amino acid residues in CDR H3 regions of heme-sensitive Abs (Fig. 5A). The overall hydropathy index (GRAVY (grand average of hydropathicity)) of the CDR H3 showed identical distribution between the two groups of Abs (data not shown).

The majority of cloned Abs used κ light chains, in both the sensitive and the non-sensitive groups of Abs (Fig. 6B). Sequence analyses of the light chain variable region genes revealed that there was a similar distribution between heme-sensitive and non-sensitive Abs in the number of somatic mutations, size of CDR L3, or physicochemical properties of CDR L3 (Fig. 6B).


In the present study, we demonstrate that seronegative immunoglobulin repertoires contain Abs that acquire the potential to recognize gp120 from HIV-1 after exposure to heme. We estimated the prevalence of these Abs in human immune repertoires and elucidated the molecular features of their variable regions associated with sensitivity to the cofactor molecule. Using a panel of 97 monoclonal Abs cloned from B cells from seronegative individuals, we found that ~24% of Abs acquire binding specificity to gp120 after exposure to heme. Most of the Abs (~70%) that acquired reactivity to gp120 also become polyreactive following heme exposure. No difference in the sensitivity to heme was seen whether Abs were originally expressed by naive, memory, or plasma cells. Because all of the studied Abs possess an identical heavy chain constant region (γ1 H-chain) and the majority is associated with a κ light chain, these results imply that the sensitivity of immunoglobulins to heme is a property determined by the sequence of the variable region genes. Most of the heme-exposed Abs acquire reactivity to three divergent variants of gp120, indicating that cofactor exposure gives these Abs the ability to adapt to the enormous sequence heterogeneity of the antigen.

Previous studies have demonstrated that exposure of some monoclonal Abs to the redox cofactor heme results in acquisition of reactivity to different structurally unrelated antigens (20, 31). Spectroscopic analyses revealed that this phenomenon is mediated by binding of the macrocyclic cofactor molecule to the variable region of immunoglobulins (7, 31). The heme molecule may provide versatile types of non-covalent interactions: hydrogen bonds, van der Waals, π-stacking, ionic, and metal coordination interactions. Such a property could explain the tendency of heme to interact with many different proteins (32, 33). The variable regions of Abs are characterized with an enormous sequence diversity that is predominantly concentrated in the CDR (30). Thus, a fraction of immunoglobulins in healthy immune repertoires may carry sequence motives that are appropriate for binding of heme or other cofactors (1, 2, 14, 17). However, the molecular characteristics of the variable regions of these Abs had not been systematically elucidated. In the current study, we sought to understand the features of the variable regions that are responsible for acquisition of novel antigen binding specificity upon exposure to cofactor. To this end, we used a repertoire of human immune Abs. No bias in VH and VL gene family usage or difference in the lengths of CDR H3 and CDR L3 regions were observed for Abs that acquire promiscuous reactivity to gp120. Our analyses demonstrated similarities in the frequencies of positive, negative, or polar amino acid residues as well as in the overall hydrophobicity of CDR H3 between cofactor-sensitive and non-sensitive Abs. However, Abs in the repertoire that acquire binding specificity to gp120 after interaction with heme possess significantly less mutated variable regions as compared with Abs that do not change their antigen binding specificity. The immunoglobulins with a lower number of somatic mutations are characterized with more pliable antigen-binding sites (34,41). Presumably, a lower number of somatic mutations in the variable region of heme-sensitive Abs will permit more extensive conformational rearrangements in these regions, increasing the probability for accommodation of the cofactor molecule to the variable region (42, 43). The absence of any typical sequence motif in variable regions of Abs that acquire binding specificity to gp120 could be explained with the high binding promiscuity of heme. Indeed, computational and experimental studies have revealed that heme-binding motifs on distinct proteins are characterized by a vast diversity of sequences and structures (44, 45). We hypothesized that heme could interact with Abs in many alternative ways, depending on the sequence of the variable region. Enormous heterogeneity of sequences of antigen-binding sites may offer different configurations appropriate for heme accommodation and for induction of novel antigen binding specificity. Indeed, our data indicated that binding intensity and the tendency for polyreactivity considerably differ between heme-sensitive Abs. This observation ruled out the possibility that heme binds to invariant sequence present in different Abs and that the binding occurs in an identical manner.

The mechanism underlying the appearance of novel antigen specificity upon binding of cofactor molecule to Abs is not yet well understood. One may envisage that heme binding to Abs induces conformational rearrangements in variable regions that result in a change of the antigen specificity. Abs with a lower number of somatic mutations would be more prone to such structural rearrangements (34,38). In addition, the unique chemistry of heme could extend the binding potential intrinsic to the polypeptide chain of Abs; thus, transient heme binding could serve as a cofactor of Abs for interaction with antigens (21). Recently, we performed a study with a prototypic heme-binding antibody that acquires reactivity to gp120 upon heme exposure, selected from the presented repertoire (31). Our data demonstrate that following interaction with heme, this Ab acquires antigen binding promiscuity and recognizes divergent variants of gp120 with quantitatively similar kinetic and thermodynamic parameters. Conversely, a broadly neutralizing Ab isolated from an HIV-1-infected patient displayed more discriminative interactions and was not able to recognize all the variants of gp120 included in the study. The results obtained in the latter study also suggest that cofactor-bound Abs use the unique chemistry of the heme molecule to recognize gp120, wherein IgG-bound heme serves as an interfacial bridge to connect Ab and gp120 (31). Importantly, heme and its analogues have been demonstrated to bind to gp120 in the V3 region (46,49). Epitope mapping predicted the same region as the most probable binding site of cofactor-bound Ab (31), thus supporting the hypothesis that the cofactor molecule serves as an interfacial bridge between the antibody and antigen. Therefore, we do not exclude the possibility that binding of heme to gp120 might result in recruitment of cofactor binding Abs in their apo-form. However, it remains to be estimated whether all cofactor-sensitive molecules in human immune repertoires utilize heme as an interfacial bridge for interacting with gp120.

Typical hemoproteins use heme as a prosthetic group for gas and electron transport and catalysis of versatile oxidative reactions (32). The absence of heme completely abrogates the functions of hemoproteins. Heme has also been demonstrated to bind to many proteins that are not conventional hemoproteins. Such an interaction promiscuity of heme plays an important role in the regulation of diverse biological processes such as gene expression, protein degradation, signal transduction, ion channel conductivity, circadian rhythms, and immune reactions (50,59). In contrast to its role in hemoproteins, the regulatory functions of heme are exerted only by transient interactions with polypeptide chains. The transient interaction of heme with a fraction of circulating Abs that could use the properties of the cofactor to extend their antigen binding repertoire may represent yet another regulatory function of heme. Thus, cofactor-binding Abs present in the circulation might be regarded as a source of antigen binding specificities in immune repertoires (60). The novel antigen specificities of these Abs would be recruited only as result of certain pathological conditions. For example, free extracellular heme is released in large quantities in the circulation in the course of different disorders such as malaria, sickle cell disease, hemolytic anemia, β-thalassemia, sepsis, and ischemia-reperfusion (25, 27, 61). It is noteworthy that HIV-1 has high sensitivity to heme, which has been explained by different mechanisms (48, 62,65). Accordingly, a recent clinical study has revealed that the incidence of HIV-1 infection in patients with sickle cell disease, who might have intravascular hemolysis and release of free heme, is significantly lower as compared with the normal population (66). Our data suggest that the fraction of cofactor-binding Abs might also contribute to the documented inhibitory effect of heme on HIV-1. Importantly, heme-bound Abs display antigen binding polyreactivity (7, 31). Our analyses revealed that a substantial fraction (16/23 or ~70%) of heme-induced gp120 binding Abs is polyreactive and could interact with unrelated protein antigens. Different studies have highlighted antigen binding polyreactivity as one of the hallmarks of neutralizing Abs generated during HIV-1 infection (67,72). In addition, the potential of some HIV-1-neutralizing Abs to recognize different structures was proposed to contribute directly to neutralization of the virus (69). Therefore, it would be important to understand whether heme-bound polyreactive Abs could also be efficient for neutralization of HIV-1.

In summary, we provide here evidence that human immune repertoires contain a significant fraction of Abs with cofactor-induced antigen binding specificity to HIV-1 gp120. These Abs possess fewer mutated variable regions than Abs that do not acquire new antigen binding specificity. Further work is required, however, to delineate the significance of Abs with cofactor-induced gp120 specificity in immune responses, to understand the molecular mechanisms of binding to gp120, and to exploit their therapeutic potential.


We thank the NIH AIDS Reagent Program, Division of AIDS, NIAID, at the National Institutes of Health for providing us vital materials.

*This work was supported by grants from INSERM, CNRS, and UPMC-Paris 6 and by grants from the Centre de Recherche des Cordeliers (Prix Jeunes Chercheurs 2008) and Agence Nationale de la Recherche (Grant ANR-13-JCV1-006-01).

An external file that holds a picture, illustration, etc.
Object name is sbox.jpgThis article contains supplemental Table 1.

2The abbreviations used are:

glycoprotein 120
pneumococcal C-polysaccharide
complementarity-determining region(s)
intravenous immunoglobulin(s).


1. Baker H., Frank O., Feingold S., Leevy C. M. (1967) Vitamin distribution in human plasma proteins. Nature 215, 84–85 [PubMed]
2. Watson C. D., Ford H. C. (1988) High-affinity binding of riboflavin and FAD by immunoglobulins from normal human serum. Biochem. Int. 16, 1067–1074 [PubMed]
3. Rajagopalan K., Pavlinkova G., Levy S., Pokkuluri P. R., Schiffer M., Haley B. E., Kohler H. (1996) Novel unconventional binding site in the variable region of immunoglobulins. Proc. Natl. Acad. Sci. U.S.A. 93, 6019–6024 [PubMed]
4. Brancaleon L., Moseley H. (2002) Effects of photoproducts on the binding properties of protoporphyrin IX to proteins. Biophys. Chem. 96, 77–87 [PubMed]
5. Zhou T., Hamer D. H., Hendrickson W. A., Sattentau Q. J., Kwong P. D. (2005) Interfacial metal and antibody recognition. Proc. Natl. Acad. Sci. U.S.A. 102, 14575–14580 [PubMed]
6. Zhu X., Wentworth P., Jr., Kyle R. A., Lerner R. A., Wilson I. A. (2006) Cofactor-containing antibodies: crystal structure of the original yellow antibody. Proc. Natl. Acad. Sci. U.S.A. 103, 3581–3585 [PubMed]
7. Dimitrov J. D., Roumenina L. T., Doltchinkova V. R., Mihaylova N. M., Lacroix-Desmazes S., Kaveri S. V., Vassilev T. L. (2007) Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J. Biol. Chem. 282, 26696–26706 [PubMed]
8. Karjalainen K., Mäkelä O. (1976) Concentrations of three hapten-binding immunoglobulins in pooled normal human serum. Eur. J. Immunol. 6, 88–93 [PubMed]
9. Farah F. S. (1973) Natural antibodies specific to the 2,4-dinitrophenyl group. Immunology 25, 217–226 [PubMed]
10. Ternynck T., Avrameas S. (1986) Murine natural monoclonal autoantibodies: a study of their polyspecificities and their affinities. Immunol. Rev. 94, 99–112 [PubMed]
11. Stopa B., Konieczny L., Piekarska B., Roterman I., Rybarska J., Skowronek M. (1997) Effect of self association of bis-ANS and bis-azo dyes on protein binding. Biochimie 79, 23–26 [PubMed]
12. Krol M., Roterman I., Drozd A., Konieczny L., Piekarska B., Rybarska J., Spolnik P., Stopa B. (2006) The increased flexibility of CDR loops generated in antibodies by Congo red complexation favors antigen binding. J. Biomol. Struct. Dyn. 23, 407–416 [PubMed]
13. Xu Y., Hixon M. S., Yamamoto N., McAllister L. A., Wentworth A. D., Wentworth P., Jr., Janda K. D. (2007) Antibody-catalyzed anaerobic destruction of methamphetamine. Proc. Natl. Acad. Sci. U.S.A. 104, 3681–3686 [PubMed]
14. Murelli R. P., Zhang A. X., Michel J., Jorgensen W. L., Spiegel D. A. (2009) Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer. J. Am. Chem. Soc. 131, 17090–17092 [PMC free article] [PubMed]
15. Parker C. G., Domaoal R. A., Anderson K. S., Spiegel D. A. (2009) An antibody-recruiting small molecule that targets HIV gp120. J. Am. Chem. Soc. 131, 16392–16394 [PMC free article] [PubMed]
16. Zhang A. X., Murelli R. P., Barinka C., Michel J., Cocleaza A., Jorgensen W. L., Lubkowski J., Spiegel D. A. (2010) A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J. Am. Chem. Soc. 132, 12711–12716 [PMC free article] [PubMed]
17. McEnaney P. J., Parker C. G., Zhang A. X., Spiegel D. A. (2012) Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol. 7, 1139–1151 [PMC free article] [PubMed]
18. McIntyre J. A. (2004) The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions. Thromb. Res. 114, 579–587 [PubMed]
19. McIntyre J. A., Wagenknecht D. R., Faulk W. P. (2005) Autoantibodies unmasked by redox reactions. J. Autoimmun. 24, 311–317 [PubMed]
20. Dimitrov J. D., Ivanovska N. D., Lacroix-Desmazes S., Doltchinkova V. R., Kaveri S. V., Vassilev T. L. (2006) Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J. Biol. Chem. 281, 439–446 [PubMed]
21. Dimitrov J. D., Vassilev T. L. (2009) Cofactor-mediated protein promiscuity. Nat. Biotechnol. 27, 892. [PubMed]
22. McIntyre J. A., Faulk W. P. (2009) Redox-reactive autoantibodies: biochemistry, characterization, and specificities. Clin. Rev. Allergy Immunol. 37, 49–54 [PubMed]
23. McIntyre J. A., Faulk W. P. (2010) Autoantibody potential of cancer therapeutic monoclonal antibodies. Int. J. Cancer 127, 491–496 [PubMed]
24. Pavlovic S., Zdravkovic N., Dimitrov J. D., Djukic A., Arsenijevic N., Vassilev T. L., Lukic M. L. (2011) Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin. Immunol. 138, 162–171 [PubMed]
25. Wagener F. A., Volk H. D., Willis D., Abraham N. G., Soares M. P., Adema G. J., Figdor C. G. (2003) Different faces of the heme-heme oxygenase system in inflammation. Pharmacol. Rev. 55, 551–571 [PubMed]
26. Kumar S., Bandyopadhyay U. (2005) Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 157, 175–188 [PubMed]
27. Gladwin M. T., Kanias T., Kim-Shapiro D. B. (2012) Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. J. Clin. Invest. 122, 1205–1208 [PMC free article] [PubMed]
28. Scheel T. (2009) [The B-cell response in the synovial tissue of patients with rheumatoid arthritis.] Ph.D. thesis, Humboldt-Universität zu Berlin
29. Scheel T., Gursche A., Zacher J., Häupl T., Berek C. (2011) V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum. 63, 63–72 [PubMed]
30. Padlan E. A. (1994) Anatomy of the antibody molecule. Mol. Immunol. 31, 169–217 [PubMed]
31. Dimitrov J. D., Planchais C., Scheel T., Ohayon D., Mesnage S., Berek C., Kaveri S. V., Lacroix-Desmazes S. (2014) A cryptic polyreactive antibody recognizes distinct clades of HIV-1 gp120 by an identical binding mechanism. J. Biol. Chem. 289, 17767–17779 [PMC free article] [PubMed]
32. Munro A. W., Girvan H. M., McLean K., Cheesman M. R., Leys D. (2009) Heme and hemeproteins, in Tetrapyrroles Birth, Life and Death (Warren M. J., Smith A. G., editors. , eds), pp. 160–207, Springer Science, New York
33. Smith A. (2009) Novel heme-protein interactions: some more radical than others, in Tetrapyrroles Birth, Life and Death (Warren M. J., Smith A. G., editors. , eds), pp. 184–207, Springer Science, New York
34. Wedemayer G. J., Patten P. A., Wang L. H., Schultz P. G., Stevens R. C. (1997) Structural insights into the evolution of an antibody combining site. Science 276, 1665–1669 [PubMed]
35. Manivel V., Sahoo N. C., Salunke D. M., Rao K. V. (2000) Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 13, 611–620 [PubMed]
36. James L. C., Roversi P., Tawfik D. S. (2003) Antibody multispecificity mediated by conformational diversity. Science 299, 1362–1367 [PubMed]
37. Nguyen H. P., Seto N. O., MacKenzie C. R., Brade L., Kosma P., Brade H., Evans S. V. (2003) Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct. Biol. 10, 1019–1025 [PubMed]
38. Jimenez R., Salazar G., Yin J., Joo T., Romesberg F. E. (2004) Protein dynamics and the immunological evolution of molecular recognition. Proc. Natl. Acad. Sci. U.S.A. 101, 3803–3808 [PubMed]
39. Wang F., Sen S., Zhang Y., Ahmad I., Zhu X., Wilson I. A., Smider V. V., Magliery T. J., Schultz P. G. (2013) Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation. Proc. Natl. Acad. Sci. U.S.A. 110, 4261–4266 [PubMed]
40. Sun S. B., Sen S., Kim N. J., Magliery T. J., Schultz P. G., Wang F. (2013) Mutational analysis of 48G7 reveals that somatic hypermutation affects both antibody stability and binding affinity. J. Am. Chem. Soc. 135, 9980–9983 [PMC free article] [PubMed]
41. Dimitrov J. D., Kaveri S. V., Lacroix-Desmazes S. (2014) Thermodynamic stability contributes to immunoglobulin specificity. Trends Biochem. Sci. 39, 221–226 [PubMed]
42. Yin J., Beuscher A. E., 4th, Andryski S. E., Stevens R. C., Schultz P. G. (2003) Structural plasticity and the evolution of antibody affinity and specificity. J. Mol. Biol. 330, 651–656 [PubMed]
43. James L. C., Tawfik D. S. (2005) Structure and kinetics of a transient antibody binding intermediate reveal a kinetic discrimination mechanism in antigen recognition. Proc. Natl. Acad. Sci. U.S.A. 102, 12730–12735 [PubMed]
44. Smith L. J., Kahraman A., Thornton J. M. (2010) Heme proteins–diversity in structural characteristics, function, and folding. Proteins 78, 2349–2368 [PubMed]
45. Kühl T., Sahoo N., Nikolajski M., Schlott B., Heinemann S. H., Imhof D. (2011) Determination of hemin-binding characteristics of proteins by a combinatorial peptide library approach. Chembiochem. 12, 2846–2855 [PubMed]
46. Debnath A. K., Jiang S., Strick N., Lin K., Haberfield P., Neurath A. R. (1994) Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. J. Med. Chem. 37, 1099–1108 [PubMed]
47. Neurath A. R., Strick N., Debnath A. K. (1995) Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120. J. Mol. Recognit. 8, 345–357 [PubMed]
48. Vzorov A. N., Dixon D. W., Trommel J. S., Marzilli L. G., Compans R. W. (2002) Inactivation of human immunodeficiency virus type 1 by porphyrins. Antimicrob. Agents Chemother. 46, 3917–3925 [PMC free article] [PubMed]
49. Dairou J., Vever-Bizet C., Brault D. (2004) Interaction of sulfonated anionic porphyrins with HIV glycoprotein gp120: photodamages revealed by inhibition of antibody binding to V3 and C5 domains. Antiviral Res. 61, 37–47 [PubMed]
50. Lathrop J. T., Timko M. P. (1993) Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science 259, 522–525 [PubMed]
51. Zhang L., Guarente L. (1995) Heme binds to a short sequence that serves a regulatory function in diverse proteins. EMBO J. 14, 313–320 [PubMed]
52. Tang X. D., Xu R., Reynolds M. F., Garcia M. L., Heinemann S. H., Hoshi T. (2003) Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels. Nature 425, 531–535 [PubMed]
53. Kaasik K., Lee C. C. (2004) Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. Nature 430, 467–471 [PubMed]
54. Raghuram S., Stayrook K. R., Huang P., Rogers P. M., Nosie A. K., McClure D. B., Burris L. L., Khorasanizadeh S., Burris T. P., Rastinejad F. (2007) Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ. Nat. Struct. Mol. Biol. 14, 1207–1213 [PMC free article] [PubMed]
55. Roumenina L. T., Radanova M., Atanasov B. P., Popov K. T., Kaveri S. V., Lacroix-Desmazes S., Frémeaux-Bacchi V., Dimitrov J. D. (2011) Heme interacts with C1q and inhibits the classical complement pathway. J. Biol. Chem. 286, 16459–16469 [PMC free article] [PubMed]
56. Sahoo N., Goradia N., Ohlenschläger O., Schönherr R., Friedrich M., Plass W., Kappl R., Hoshi T., Heinemann S. H. (2013) Heme impairs the ball-and-chain inactivation of potassium channels. Proc. Natl. Acad. Sci. U.S.A. 110, E4036–E4044 [PubMed]
57. Frimat M., Tabarin F., Dimitrov J. D., Poitou C., Halbwachs-Mecarelli L., Fremeaux-Bacchi V., Roumenina L. T. (2013) Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122, 282–292 [PubMed]
58. Belcher J. D., Chen C., Nguyen J., Milbauer L., Abdulla F., Alayash A. I., Smith A., Nath K. A., Hebbel R. P., Vercellotti G. M. (2014) Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 123, 377–390 [PubMed]
59. Kühl T., Imhof D. (2014) Regulatory Fe(II/III) heme: the reconstruction of a molecule's biography. Chembiochem. 15, 2024–2035 [PubMed]
60. Planchais C., Gupta N., Kaveri S. V., Lacroix-Desmazes S., Dimitrov J. D. (2013) [Post-translational diversification of immunoglobulins specificity]. Med. Sci. (Paris) 29, 937–940 [PubMed]
61. Larsen R., Gozzelino R., Jeney V., Tokaji L., Bozza F. A., Japiassú A. M., Bonaparte D., Cavalcante M. M., Chora A., Ferreira A., Marguti I., Cardoso S., Sepúlveda N., Smith A., Soares M. P. (2010) A central role for free heme in the pathogenesis of severe sepsis. Sci. Transl. Med. 2, 51ra71 [PubMed]
62. Devadas K., Dhawan S. (2006) Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J. Immunol. 176, 4252–4257 [PubMed]
63. Levere R. D., Gong Y. F., Kappas A., Bucher D. J., Wormser G. P., Abraham N. G. (1991) Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine. Proc. Natl. Acad. Sci. U.S.A. 88, 1756–1759 [PubMed]
64. Staudinger R., Abraham N. G., Levere R. D., Kappas A. (1996) Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs. Proc. Assoc. Am. Physicians 108, 47–54 [PubMed]
65. Argyris E. G., Vanderkooi J. M., Venkateswaran P. S., Kay B. K., Paterson Y. (1999) The connection domain is implicated in metalloporphyrin binding and inhibition of HIV reverse transcriptase. J. Biol. Chem. 274, 1549–1556 [PubMed]
66. Nouraie M., Nekhai S., Gordeuk V. R. (2012) Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study. Sex Transm. Infect. 88, 528–533 [PMC free article] [PubMed]
67. Ditzel H. J., Itoh K., Burton D. R. (1996) Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. J. Immunol. 157, 739–749 [PubMed]
68. Haynes B. F., Fleming J., St Clair E. W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R. M., Plonk K., Staats H. F., Ortel T. L., Liao H. X., Alam S. M. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906–1908 [PubMed]
69. Mouquet H., Scheid J. F., Zoller M. J., Krogsgaard M., Ott R. G., Shukair S., Artyomov M. N., Pietzsch J., Connors M., Pereyra F., Walker B. D., Ho D. D., Wilson P. C., Seaman M. S., Eisen H. N., Chakraborty A. K., Hope T. J., Ravetch J. V., Wardemann H., Nussenzweig M. C. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591–595 [PMC free article] [PubMed]
70. Mouquet H., Klein F., Scheid J. F., Warncke M., Pietzsch J., Oliveira T. Y., Velinzon K., Seaman M. S., Nussenzweig M. C. (2011) Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One 6, e24078. [PMC free article] [PubMed]
71. Zhu Z., Qin H. R., Chen W., Zhao Q., Shen X., Schutte R., Wang Y., Ofek G., Streaker E., Prabakaran P., Fouda G. G., Liao H. X., Owens J., Louder M., Yang Y., Klaric K. A., Moody M. A., Mascola J. R., Scott J. K., Kwong P. D., Montefiori D., Haynes B. F., Tomaras G. D., Dimitrov D. S. (2011) Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J. Virol. 85, 11401–11408 [PMC free article] [PubMed]
72. Liao H. X., Lynch R., Zhou T., Gao F., Alam S. M., Boyd S. D., Fire A. Z., Roskin K. M., Schramm C. A., Zhang Z., Zhu J., Shapiro L., NISC Comparative Sequencing Program, Mullikin J. C., Gnanakaran S., Hraber P., Wiehe K., Kelsoe G., Yang G., Xia S. M., Montefiori D. C., Parks R., Lloyd K. E., Scearce R. M., Soderberg K. A., Cohen M., Kamanga G., Louder M. K., Tran L. M., Chen Y., Cai F., Chen S., Moquin S., Du X., Joyce M. G., Srivatsan S., Zhang B., Zheng A., Shaw G. M., Hahn B. H., Kepler T. B., Korber B. T., Kwong P. D., Mascola J. R., Haynes B. F. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469–476 [PMC free article] [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology